SequelSEC

CorMedix Inc. CRMD

Pharmaceutical Preparations · CIK 0001410098 · Fiscal year ends 1231

Revenue
$311.71M
Fiscal year ended 2025-12-31
Operating income
$150.14M
Fiscal year ended 2025-12-31
Free cash flow
$172.79M
Fiscal year ended 2025-12-31

CorMedix Inc. (CRMD) reported revenue of $311.71M and net income of $163.06M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from CorMedix Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

CorMedix Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Revenue$311.71M$43.47M$65.41K$190.94K$239.23K$283.27K$429.80K$329.33K$224.10K$210.13K
Cost of revenueUnavailable$3.03M$3.73K$148.94K$204.85K$373.23K$396.79K$114.96K$366.67KUnavailable
Gross profitUnavailable$40.28M$61.67K$42.00K$34.38K-$89.97K$33.01K$214.36K-$142.57KUnavailable
Operating income$150.14M-$22.36M-$30.62M-$29.44M-$27.22M-$21.01M-$26.86M-$32.92M-$24.76M-$16.65M
Net income$163.06M-$17.93M-$29.70M-$28.21M-$22.03M-$16.43M-$26.83M-$33.01M-$24.64M-$18.19M
Research & development$19.33M$3.94M$10.68M$13.13M$13.38M$11.05M$18.82M$24.49M$15.74M$6.28M
Weighted-average diluted sharesUnavailableUnavailableshares 40.27Mshares 37.67MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income$150.02M-$19.32M-$30.29M-$29.46M-$27.20M-$21.49M-$26.83M-$33.01M-$24.64M-$18.19M
Income tax expense-$13.04M-$1.40M-$585.62K-$1.25M-$5.17M-$5.06MUnavailableUnavailableUnavailableUnavailable
Diluted EPS$2.04$-0.30$-0.74$-0.75UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$106.27M$58.70M$20.01M$16.35M$13.88M$9.87M$8.07MUnavailableUnavailableUnavailable
General & administrative$68.22M$29.96MUnavailableUnavailableUnavailableUnavailable$8.07M$8.65M$8.88M$10.26M
Selling & marketing$38.05M$28.74MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

CorMedix Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Cash & equivalents$144.84M$40.65M$43.15M$53.32M$41.91M$16.35M$17.62M$10.38M$8.06M$11.82M
Total assets$826.14M$118.85M$62.04M$68.95M$49.31M$29.48M$18.83M$13.45M$21.91M$37.10M
Current assets$367.05M$114.58M$59.55M$66.47M$48.18M$29.35M$18.67M$13.27M$21.83M$37.06M
Total liabilities$420.84M$34.19M$6.98M$6.15M$5.09M$5.83M$13.89M$6.26M$4.09M$3.09M
Current liabilities$174.27M$33.84M$6.31M$5.35M$4.16M$5.83M$7.77M$6.26M$4.09M$3.06M
Total equity incl. NCI$405.31M$84.66M$55.06M$62.80M$44.22M$23.65M$4.93M$7.19M$17.81M$34.01M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$29.72M$7.60MUnavailable$3.01K$143.56K$338.46K$428.52K$594.19K$166.73K$376.57K
Accounts receivable$171.23M$51.65MUnavailable$45.37K$3.36K$35$10.90K$64.15K$12.01K$315.77K
Goodwill$30.00MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$7.88M$1.72M$2.20M$2.21M$1.13M$1.02M$2.59M$1.81M$1.65M$1.71M

Cash flow

CorMedix Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Operating cash flow$175.05M-$50.62M-$24.36M-$21.16M-$21.97M-$15.05M-$23.70M-$28.59M-$22.27M-$12.53M
Capital expenditures$2.26M$116.00K$219.36K$1.43M$112.64K$36.57K$48.89K$151.99K$58.72K$15.45K
Investing cash flow-$308.43M$21.23M-$3.71M-$9.13M$7.43M-$12.02M$1.56M$10.36M$11.42M-$23.61M
Financing cash flow$238.45M$26.32M$17.90M$41.76M$40.10M$25.80M$29.40M$20.52M$7.09M$43.63M
Net change in cash$105.07M-$3.07M-$10.18M$11.45M$25.57M-$1.27M$7.24M$2.32M-$3.75M$7.48M
Stock-based compensation$13.83M$6.13M$4.07M$5.04M$2.50M$2.44M$1.11M$1.66M$1.34M$3.23M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

CorMedix Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Free cash flow$172.79M-$50.73M-$24.58M-$22.58M-$22.08M-$15.09M-$23.75M-$28.74M-$22.32M-$12.54M
Gross margin88.5%92.7%94.3%22.0%14.4%-31.8%7.7%65.1%-63.6%-51.7%
Operating margin48.2%-51.4%-46819.9%-15417.5%-11378.4%-7416.3%-6250.4%-9997.4%-11048.8%-7925.6%
FCF margin55.4%-116.7%-37573.5%-11826.2%-9229.7%-5326.7%-5525.7%-8726.6%-9961.5%-5968.8%
SBC / revenue4.4%14.1%6221.7%2641.0%1044.9%861.2%258.4%503.8%595.8%1535.1%
Current ratio2.11x3.39x9.44x12.44x11.58x5.04x2.40x2.12x5.34x12.11x
Revenue YoY growth617.0%Unavailable-65.7%-20.2%-15.5%-34.1%30.5%47.0%6.7%Unavailable
Net margin52.3%-41.2%-45409.9%-14774.7%-9207.7%-5801.3%-6242.4%-10023.4%-10996.5%-8655.4%
R&D / revenue6.2%9.1%16327.6%6878.2%5591.7%3902.0%4379.4%7435.2%7021.4%2989.5%
CapEx / revenue0.7%0.3%335.4%746.5%47.1%12.9%11.4%46.2%26.2%7.4%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate-8.7%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CRMD in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2025-12-31

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2015-12-31

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.